Document is current
Any future updates will be listed below
-
Authors
Chen, Shu-Ling
Xiao, Han
Xie, Zong-Lin
Shen, Jing-Xian
Chen, Ze-Bin
Wang, Yuan-Qi
Li, Bin
Peng, Zhen-Wei
Kuang, Ming
Lai, Jia-Ming
Peng, Sui
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81770608, 81801703)
National Science Fund for Distinguished Young Scholars (81825013)
Natural Science Foundation of Guangdong Province (2018A030310282)
National high level talents special support plan--Ten thousand plan--Young top-notch talent support program (-)
Kelin Outstanding Young Scientist of the First Affiliated Hospital of Sun Yet-sen University (2017)
- License Information
-
More Information
Article History
Received: 14 September 2019
Revised: 1 December 2019
Accepted: 17 December 2019
First Online: 11 February 2020
Compliance with ethical standards
:
: The scientific guarantor of this publication is Sui Peng.
: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: One of the authors (Bin Li) has significant statistical expertise.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in the <i>American Journal of Translational Research</i>. The former article focused on characteristics of patients with MVI(+). To explore the role of MVI in guidance of treatments for HBV+ recurrent intermediate-advanced HCC, we limited the population to HBV+ patients and further added data of patients with MVI(−) at primary resection. Therefore, the role of MVI in treatment selection for HBV+ rHCC patients could only be evaluated in this study.
: • retrospective• observational• multicenter study
